Biotech Deal-Making as Industry Barometer
This article was originally published in Start Up
Executive Summary
Given the overriding interest among investors in liquidity, corporate dealmaking in biotech now only very rarely serves as validation for IPOs, let alone boosting stock prices. Instead, there's been a much sharper focus on the strategic value of dealmaking. It has become the means by which a company can protect the long-term value of an asset or asset base for maximum flexibility in the future.